<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04927975</url>
  </required_header>
  <id_info>
    <org_study_id>M19-051</org_study_id>
    <secondary_id>2021-000081-15</secondary_id>
    <nct_id>NCT04927975</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of Upadacitinib in Subjects With Non-Segmental Vitiligo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitiligo is a common chronic autoimmune disease that causes the body's immune system to&#xD;
      attack its own pigment producing skin cells. This study is to evaluate how safe and effective&#xD;
      upadacitinib is in participants with non-segmental vitiligo. Adverse effects and change in&#xD;
      disease activity will be assessed.&#xD;
&#xD;
      Upadacitinib is being evaluated for the treatment of non-segmental vitiligo. The study will&#xD;
      enroll approximately 160 participants aged 18-65 with non-segmental vitiligo in 5 treatment&#xD;
      arms across 35 sites worldwide.&#xD;
&#xD;
      Participants will either receive study drug vs placebo oral tablets once daily (QD) for 24&#xD;
      weeks (Period A). In Period B (up to 52 weeks), participants who received placebo during the&#xD;
      first 24 weeks will switch to study drug. Participants who received study drug during the&#xD;
      first 24 weeks, will continue to receive study drug.&#xD;
&#xD;
      There may be higher treatment burden for participants in this trial compared to their&#xD;
      standard of care. Participants will attend regular visits during the study at a hospital or&#xD;
      clinic. The effect of the treatment will be checked by medical assessments, blood tests,&#xD;
      checking for side effects and completing questionnaires.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 8, 2021</start_date>
  <completion_date type="Anticipated">December 19, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 7, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in Facial-Vitiligo Area Scoring Index (F-VASI)</measure>
    <time_frame>At 24 weeks</time_frame>
    <description>The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. The F-VASI includes contributions from the face, with a possible range from 0 to 3.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving F-VASI 75 (≥ 75% Improvement in F-VASI From Baseline)</measure>
    <time_frame>At 24 weeks</time_frame>
    <description>The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. The F-VASI includes contributions from the face, with a possible range from 0 to 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving F-VASI 50 (≥ 50% Improvement in F-VASI From Baseline)</measure>
    <time_frame>At 24 weeks</time_frame>
    <description>The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. The F-VASI includes contributions from the face, with a possible range from 0 to 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Total Vitiligo Area Scoring Index (T-VASI) 50 (≥ 50% Improvement in T-VASI From Baseline)</measure>
    <time_frame>At 24 weeks</time_frame>
    <description>The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. It is based on a composite estimate of the overall area of vitiligo patches, measured by the number of hand units (palm plus 5 digits = 1% body surface area [BSA]) multiplied by the degree of depigmentation within each affected area (0%, 10%, 25%, 50%, 75%, 90%, or 100%). The T-VASI is calculated using a formula that includes contributions from all body regions, with a possible range from 0 to 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in T-VASI</measure>
    <time_frame>At 24 weeks</time_frame>
    <description>The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. It is based on a composite estimate of the overall area of vitiligo patches, measured by the number of hand units (palm plus 5 digits = 1% body surface area [BSA]) multiplied by the degree of depigmentation within each affected area (0%, 10%, 25%, 50%, 75%, 90%, or 100%). The T-VASI is calculated using a formula that includes contributions from all body regions, with a possible range from 0 to 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Vitiligo Quality-of-Life (VitiQoL) Instrument Total Score</measure>
    <time_frame>At 24 weeks</time_frame>
    <description>The VitiQoL is a validated questionnaire used in clinical trials to assess stigma-related vitiligo impacts. The VitiQoL uses subject-elicited social, affective, and behavior items, asking the subject's appraisal of the vitiligo-related impacts over the last month. Fifteen items are scored on a 7-point scale ranging from 0 (&quot;Not at all&quot;) to 6 (&quot;All of the time&quot;). Item scores (0 to 6) are summed to provide a total score range of 0 to 90; higher scores indicate greater impairment of quality of life (QoL).</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Non-Segmental Vitiligo</condition>
  <arm_group>
    <arm_group_label>Dose A of Upadacitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will receive dose A of upadacitinib orally once daily (QD) for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose B of Upadacitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will receive dose B of upadacitinib orally QD for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose C of Upadacitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will receive dose C of upadacitinib orally QD for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Followed by Dose A of Upadacitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will receive placebo for 24 weeks followed by dose A of upadacitinib orally QD for 28 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Followed by Dose B of Upadacitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will receive placebo for 24 weeks followed by dose B of upadacitinib orally QD for 28 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Upadacitinib</intervention_name>
    <description>Oral tablets</description>
    <arm_group_label>Dose A of Upadacitinib</arm_group_label>
    <arm_group_label>Dose B of Upadacitinib</arm_group_label>
    <arm_group_label>Dose C of Upadacitinib</arm_group_label>
    <arm_group_label>Placebo Followed by Dose A of Upadacitinib</arm_group_label>
    <arm_group_label>Placebo Followed by Dose B of Upadacitinib</arm_group_label>
    <other_name>ABT-494</other_name>
    <other_name>RINVOQ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral tablets</description>
    <arm_group_label>Placebo Followed by Dose A of Upadacitinib</arm_group_label>
    <arm_group_label>Placebo Followed by Dose B of Upadacitinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of non-segmental vitiligo (NSV) and no segmental or localized&#xD;
             vitiligo.&#xD;
&#xD;
          -  Participants with all of the following at Screening and Baseline.&#xD;
&#xD;
               -  Visits: ≥ 0.5 F-VASI and ≥ 5 total vitiligo area scoring index (T-VASI).&#xD;
&#xD;
               -  Participants who have had prior exposure to immunomodulatory biologic therapy,&#xD;
                  for any indications, but discontinued the biologic therapy prior to the first&#xD;
                  dose of study drug. Recommended washout periods for biologic therapies include ≥&#xD;
                  4 weeks for etanercept; ≥ 8 weeks for adalimumab, infliximab, certolizumab,&#xD;
                  golimumab, abatacept, tocilizumab, and ixekizumab; ≥ 16 weeks for secukinumab;&#xD;
                  and ≥ 12 weeks for ustekinumab. For biologic therapies not specified, therapies&#xD;
                  must be discontinued at least 5 times the mean terminal elimination half-life of&#xD;
                  a drug or 3 months prior to Baseline, whichever is longer.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with segmental or localized vitiligo.&#xD;
&#xD;
          -  Participants with other skin conditions that would interfere with evaluation of&#xD;
             vitiligo, participants with uncontrolled thyroid disease, and participants with &gt; 33%&#xD;
             leukotrichia on the face or &gt; 33% leukotrichia on the body (including face).&#xD;
&#xD;
          -  Participants previously treated with any topical or systemic janus kinase (JAK)&#xD;
             inhibitor or permanent skin bleaching agents.&#xD;
&#xD;
          -  Participants treated with any systemic vitiligo therapy (e.g., methotrexate,&#xD;
             mycophenolate mofetil, corticosteroids), supplemental vitiligo therapy&#xD;
             (antioxidants/vitamins/herbal medicine/traditional Chinese medicine), and/or topical&#xD;
             vitiligo therapy including permanent or temporary tattoos within a minimum of 30 days&#xD;
             prior to the first dose of study drug (Note: Camouflage and makeup may be used).&#xD;
&#xD;
          -  Participants treated with any phototherapy, including excimer (or other forms of laser&#xD;
             therapy), within a minimum of 12 weeks prior to the first dose of study drug.&#xD;
&#xD;
          -  Participants have history of malignancy other than successfully treated non-melanoma&#xD;
             skin cancer (NMSC) or localized carcinoma in situ of the cervix.&#xD;
&#xD;
          -  Recent (within past 6 months) cerebrovascular accident, myocardial infarction,&#xD;
             coronary stenting, and aorto-coronary bypass surgery;&#xD;
&#xD;
          -  History of an organ transplant which requires continued immunosuppression;&#xD;
&#xD;
          -  History of gastrointestinal (GI) perforation (other than due to appendicitis or&#xD;
             mechanical injury), diverticulitis, or significantly increased risk for GI perforation&#xD;
             per investigator judgment;&#xD;
&#xD;
          -  Conditions that could interfere with drug absorption including but not limited to&#xD;
             short bowel syndrome or gastric bypass surgery; subjects with a history of gastric&#xD;
             banding/segmentation are not excluded;&#xD;
&#xD;
          -  Uncontrolled thyroid disease;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ABBVIE INC.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>844-663-3742</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California Irvine /ID# 229390</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697-1385</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stanford University /ID# 228000</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clearlyderm Dermatology /ID# 227993</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33428</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>New Horizon Research Center /ID# 229403</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33165-3372</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Park Avenue Dermatology, PA /ID# 229400</name>
      <address>
        <city>Orange Park</city>
        <state>Florida</state>
        <zip>32073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ForCare Clinical Research /ID# 228010</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613-1244</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dawes Fretzin, LLC /ID# 227996</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center /ID# 228087</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111-1552</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UMass Memorial Medical Center /ID# 228066</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Michigan Center for Research Company /ID# 228054</name>
      <address>
        <city>Clarkston</city>
        <state>Michigan</state>
        <zip>48346</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hamzavi Dermatology /ID# 228056</name>
      <address>
        <city>Fort Gratiot</city>
        <state>Michigan</state>
        <zip>48059</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Remington-Davis Clinical Research /ID# 229401</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Essential Medical Research, LLC /ID# 228074</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74137-2842</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oregon Dermatology and Research Center /ID# 228007</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oregon Medical Res Center PC /ID# 228073</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97223</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina /ID# 228067</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>International Clinical Research - Tennessee LLC /ID# 228059</name>
      <address>
        <city>Murfreesboro</city>
        <state>Tennessee</state>
        <zip>37130-2450</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bellaire Dermatology /ID# 228004</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at Houston /ID# 229399</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-1501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia Clinical Research, Inc. /ID# 228050</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. Chih-ho Hong Medical Inc. /ID# 228403</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3R 6A7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wiseman Dermatology Research /ID# 228410</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3M 3Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Toronto /ID# 228401</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4W 2N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>K. Papp Clinical Research /ID# 228877</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre de recheche dermatologique du Quebec Metropolitain /ID# 228388</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1V 4X7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chu de Nice-Hopital L'Archet Ii /Id# 228192</name>
      <address>
        <city>Nice</city>
        <state>Alpes-Maritimes</state>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Andre /ID# 228193</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Henri Mondor /ID# 228198</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>HCL - Hopital Edouard Herriot /ID# 228194</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse - Hopital Larrey /ID# 228196</name>
      <address>
        <city>Toulouse</city>
        <zip>31400</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nagoya City University Hospital /ID# 228725</name>
      <address>
        <city>Nagoya shi</city>
        <state>Aichi</state>
        <zip>467-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nippon Medical School Hospital /ID# 230361</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical University Hospital /ID# 230288</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yamagata University Hospital /ID# 230362</name>
      <address>
        <city>Yamagata-shi</city>
        <state>Yamagata</state>
        <zip>990-9585</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yamanashi Prefectural Central Hospital /ID# 229441</name>
      <address>
        <city>Kofu-shi</city>
        <state>Yamanashi</state>
        <zip>400-8506</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.rxabbvie.com/</url>
    <description>This clinical study may be evaluating a usage that is not currently FDA approved. Please see US Prescribing Information for approved uses.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 11, 2021</study_first_submitted>
  <study_first_submitted_qc>June 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vitiligo</keyword>
  <keyword>Non-segmental vitiligo (NSV)</keyword>
  <keyword>Upadacitinib</keyword>
  <keyword>ABT-494</keyword>
  <keyword>RINVOQ</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitiligo</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Upadacitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

